A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy

High-grade neuroendocrine carcinoma differs from usual neuroendocrine carcinoma, and its prognosis is dismal. In this case report, a case of high-grade neuroendocrine carcinoma that improved with bevacizumab plus modified FOLFOX6 as the fourth-line chemotherapy is presented. A 29-year-old male with...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Satoshi, Honma, Rio, Taguchi, Jun, Amano, Toraji, Shimizu, Yasushi, Kinoshita, Ichiro, Kubota, Kanako, Matsuno, Yoshihiro, Dosaka-Akita, Hirotoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2011
Materias:
Published: May 2011
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124459/
https://www.ncbi.nlm.nih.gov/pubmed/21734880
http://dx.doi.org/10.1159/000328802
_version_ 1782207092301496320
author Takeuchi, Satoshi
Honma, Rio
Taguchi, Jun
Amano, Toraji
Shimizu, Yasushi
Kinoshita, Ichiro
Kubota, Kanako
Matsuno, Yoshihiro
Dosaka-Akita, Hirotoshi
author_facet Takeuchi, Satoshi
Honma, Rio
Taguchi, Jun
Amano, Toraji
Shimizu, Yasushi
Kinoshita, Ichiro
Kubota, Kanako
Matsuno, Yoshihiro
Dosaka-Akita, Hirotoshi
author_sort Takeuchi, Satoshi
collection PubMed
description High-grade neuroendocrine carcinoma differs from usual neuroendocrine carcinoma, and its prognosis is dismal. In this case report, a case of high-grade neuroendocrine carcinoma that improved with bevacizumab plus modified FOLFOX6 as the fourth-line chemotherapy is presented. A 29-year-old male with a huge liver tumor was diagnosed with high-grade neuroendocrine carcinoma originating from the liver. Multiple liver and bone metastases were found one month after surgery. He was treated with three chemotherapy regimens used for the management of small-cell lung cancer with extensive disease. However, none of them could be maintained because of tumor progression. He was then treated with bevacizumab plus modified FOLFOX6 as the fourth-line regimen. Dramatic tumor shrinkage was obtained, and a partial response was achieved. This case suggests that high-grade neuroendocrine carcinoma can be treated with bevacizumab in combination with cytotoxic chemotherapy.
format Online
Article
Text
id pubmed-3124459
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-31244592011-07-06 A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy Takeuchi, Satoshi Honma, Rio Taguchi, Jun Amano, Toraji Shimizu, Yasushi Kinoshita, Ichiro Kubota, Kanako Matsuno, Yoshihiro Dosaka-Akita, Hirotoshi Case Rep Oncol Published: May 2011 High-grade neuroendocrine carcinoma differs from usual neuroendocrine carcinoma, and its prognosis is dismal. In this case report, a case of high-grade neuroendocrine carcinoma that improved with bevacizumab plus modified FOLFOX6 as the fourth-line chemotherapy is presented. A 29-year-old male with a huge liver tumor was diagnosed with high-grade neuroendocrine carcinoma originating from the liver. Multiple liver and bone metastases were found one month after surgery. He was treated with three chemotherapy regimens used for the management of small-cell lung cancer with extensive disease. However, none of them could be maintained because of tumor progression. He was then treated with bevacizumab plus modified FOLFOX6 as the fourth-line regimen. Dramatic tumor shrinkage was obtained, and a partial response was achieved. This case suggests that high-grade neuroendocrine carcinoma can be treated with bevacizumab in combination with cytotoxic chemotherapy. S. Karger AG 2011-05-24 /pmc/articles/PMC3124459/ /pubmed/21734880 http://dx.doi.org/10.1159/000328802 Text en Copyright © 2011 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published: May 2011
Takeuchi, Satoshi
Honma, Rio
Taguchi, Jun
Amano, Toraji
Shimizu, Yasushi
Kinoshita, Ichiro
Kubota, Kanako
Matsuno, Yoshihiro
Dosaka-Akita, Hirotoshi
A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
title A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
title_full A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
title_fullStr A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
title_full_unstemmed A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
title_short A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
title_sort case of high-grade neuroendocrine carcinoma that improved with bevacizumab plus modified folfox6 as the fourth-line chemotherapy
topic Published: May 2011
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124459/
https://www.ncbi.nlm.nih.gov/pubmed/21734880
http://dx.doi.org/10.1159/000328802
work_keys_str_mv AT takeuchisatoshi acaseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT honmario acaseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT taguchijun acaseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT amanotoraji acaseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT shimizuyasushi acaseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT kinoshitaichiro acaseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT kubotakanako acaseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT matsunoyoshihiro acaseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT dosakaakitahirotoshi acaseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT takeuchisatoshi caseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT honmario caseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT taguchijun caseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT amanotoraji caseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT shimizuyasushi caseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT kinoshitaichiro caseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT kubotakanako caseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT matsunoyoshihiro caseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy
AT dosakaakitahirotoshi caseofhighgradeneuroendocrinecarcinomathatimprovedwithbevacizumabplusmodifiedfolfox6asthefourthlinechemotherapy

Ejemplares similares